This trial is evaluating whether Rifaximin will improve 3 primary outcomes in patients with Liver Diseases. Measurement will happen over the course of 7 days.
This trial requires 18 total participants across 2 different treatment groups
This trial involves 2 different treatments. Rifaximin is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 4 and have been shown to be safe and effective in humans.
The prevalence of liver diseases in China is estimated as over 90%. Hepatitis B is the most common cause of hepatitis in Chinese population and can be effectively controlled by immunization against the virus.
liver disease treatments vary according to the type of liver disease and the presence and severity of hepatic dysfunction.\n\n- Liver Disease - Overview U.S. National Library of Medicine\n- "
"Bulbophyllum brachystachyum\n\nBulbophyllum brachystachyum is a species of orchid in the genus "Bulbophyllum".
The most commonly found causes of liver diseases in this study were virus infection, alcoholic liver disease, drug abuse, and other drugs. More than 90% of cirrhosis in the study was diagnosed after an infection with hepatitis B or C virus.
Lying abdominal pain, itch, swollen limb(s), tender spleen and tender liver(s) are the major signs due to liver diseases. Hepatomegaly (particularly in the right upper quadrant) is the most common finding. Hepatomegaly and ochre discolouration of the skin
In the United States more than 1.8 million adults per year have a chronic disease that was related to excessive alcohol consumption. Most of these adults were men, and many were nondrinkers or nondieters. There were no racial or ethnic differences in the chronic liver diseases or the risk factors cited by participants in the U.S. National Health and Nutrition Examination Survey (2001-2002).
Liver diseases can be cured. The key to success lies in early diagnosis and treatment of the disease using proper therapeutic modalities, such as antibiotics and antiviral therapy. However, none of this has ever been proven in clinical trials to date and as such it remains a research area requiring further efforts.
The primary cause of hepatic degeneration are [alcohol, chronic viral infection, chronic drug, alcoholic steatohepatitis, hepatitis C, \nprimary biliary cirrhosis, \nprimary sclerosing cholangitis, \nalcoholic hepatitis, \nhyper-vitaminosis A and hepatitis B.]<br>[with]<br>[Consequences:-<br>alcoholic hepatitis can be cured and the other complications can be avoided if all patients who suffer from alcoholic hepatitis are treated. Patients with chronic viral infections like Hepatitis C and the Hepatitis B virus should be vaccinated at the earliest feasible day.
Treatment with pentoxifylline has been shown to have some positive effects to ameliorate liver damage in chronic liver disease, and the role of pentoxifylline needs to be further explored. Antioxidant therapies might produce promising results in the potential of liver diseases, and further experimentation is needed.
Liver diseases can be so serious, and in serious cases, it needs immediate medical consultation or referral. The serious liver diseases are [hepatitis B virus (HBV) reactivation, HBV-ACL] (when you are being treated with anti-HCV therapies like PEG-IFN, ribavirin, etc.
Rifaximin was found to be more effective than placebo to reduce stools in patients with active idiopathic non-biliary spasm. Rifaximin's effectiveness was equivalent to antibiotics. Further studies must be conducted to further evaluate the treatment's efficacy.
The liver is the central organ of metabolizing and excreting ingested lipids and carbohydrates. In general, when the liver is no longer able to process them, that condition generally arises when the child reaches the age 12 years (5 years after the age of first-time exposure to an identifiable cause). Liver diseases can begin to appear later if people are more severely exposed to toxins such as inorganic hepatocarcinogens, environmental tobacco smoke (e.g. carbon tetrachloride, a gasoline additive), alcohol, or heavy metals accumulating in tissues: the process has usually proceeded for about 15 years when it becomes clinically obvious.
Rifaximin has good tolerability, the best absorption of pectin-degrading enzymes, the ability to cross the epithelial mucosal barrier, and good in vivo activity by the oral route. Rifaximin might be considered as a therapy for intestinal infections, metabolic diseases, and inflammatory bowel diseases.